HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Edgar G. Chedrawy Dao M. Nguyen Dominique Shum-Tim Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chedrawy, E. G. Articles by Chiu, R. C. J. Search for Related Content PubMed PubMed Citation Articles by Chedrawy, E. G. Articles by Chiu, R. C. J. Related Collections Molecular biology

J Thorac Cardiovasc Surg 2002;124:584-590
© 2002 The American Association for Thoracic Surgery

Surgery for Acquired Cardiovascular Disease (ACD)

Incorporation and integration of implanted myogenic and stem cells into native myocardial fibers: Anatomic basis for functional improvements

From the Division of Cardiac Surgery, McGill University Health Center, Montreal, Quebec, Canada.

Received for publication May 15, 2001. Revisions requested Sept 19, 2001; revisions received Nov 16, 2001. Accepted for publication Dec 27, 2001. Address for reprints: Ray C. J. Chiu, MD, The Montreal General Hospital/MUHC, 1650 Cedar Ave, Room C9-169, Montreal, Quebec H3G 1A4, Canada (E-mail: rchiu{at}po-box.mcgill.ca).

	Abstract

Top Abstract Introduction Methods Results Discussion Appendix: Discussion References

 
Background: Myoblasts and stem cells implanted into myocardium can differentiate into myocytes and may functionally improve impaired ventricles. For implanted cells to actually contribute to the synchronous contractions of the heart, however, they must be anatomically integrated with the existing native myocardial fibers.
Methods: Isogenic Lewis rats were used as donors and recipients to simulate clinical autotransplantation. Either skeletal myoblasts or marrow stromal stem cells were isolated from donors, culture expanded, and labeled with 4',6-diamidino-2-phenylindole (4',6-diamidino-2-phenylindole). Labeled cells were then injected into the myocardium of recipients. At intervals specimens were obtained, sectioned, and stained with hematoxylin and eosin and immunohistochemically against connexin-43 to demonstrate gap junctions (intercalated discs).
Results: At 1 week the labeled cells were still undifferentiated, but early expression of connexin-43 could be detected at contact points between the implanted cells and the native myocytes. By 4 to 6 weeks, labeled, fully differentiated myocytes could be seen to interconnect among themselves and with native cardiomyocytes by means of intercalated discs. In sections parallel to the myofibers, full integration of new labeled myocytes with the native myofiber cells could be observed. Furthermore, the labeled myofibers were in parallel with the native, unlabeled fibers. We postulate that such supracellular structural integration was enhanced by fiber stretching during cardiac contractions, sending signals for cellular reorientation and incorporation, in which the cytoskeletal system may play an important role.
Conclusion: We conclude that implanted precursor cells can be integrated into native myocardial structure so as to contribute to myocardial function. Direct cell-to-cell contact seems to be an important signaling mechanism, which has implications for cellular implantation strategies.

	Introduction

Top Abstract Introduction Methods Results Discussion Appendix: Discussion References

 
The aim of cell replacement therapy for heart failure is to replace cardiomyocytes irreversibly lost to necrosis and apoptosis. Various donor cell sources have been studied, including fetal cardiomyocytes, ¹ myoblasts, ^2-7 and embryonic and adult stem cells. ^8-10

Use of autologous myoblasts (satellite cells) ⁶ and marrow stromal stem cells (MSCs) ⁹ has clinical advantages, because these cells are readily available for every patient and their use does not require immunosuppression. Our earlier studies and those of others have confirmed that these cells are able to survive and undergo myogenic differentiation on implantation into myocardium. ¹¹ Although the ultimate phenotypic expression of implanted skeletal myoblasts remains controversial at this time, ⁴ there is strong evidence that MSCs can be induced to express a cardiomyocytic phenotype, both in vitro ⁸ and in vivo. ⁹ Such differentiation of MSCs, which are now known to be pluripotent stem cells residing in the bone marrow of both immature and mature subjects, has been investigated and elucidated at molecular and cellular levels. ¹² To achieve the clinical goal of using these cells to provide new contractile muscle capable of assisting the ventricular function of a failing heart, however, we need additional evidence that such cells can in fact be incorporated and integrated into the supracellular anatomic architecture of the myocardium.

Unlike other striated muscles, the myocardium is uniquely structured to achieve synchronous, all-or-none contractions in response to a depolarizing electric signal. Thus the cardiomyocytes are interconnected by specialized cell-cell junctions, histologically known as intercalated discs, to form syncytial fibers. These fiber bundles ¹³ are arranged in complex layers of circular, oblique, and longitudinal orientations to form the ventricular wall, optimized to perform its physiologic functions. This report explores the feasibility of supracellular integration of the neocardiomyocytes and myofibers derived from the implanted myoblasts and stem cells by extending and reappraising the observations made in our recent studies. ^6,9 On the basis of these findings and the existing information on cellular mechanotransduction and cytoskeletal function, ¹⁴ we further propose a mechanistic hypothesis as to how such integration may take place, thus providing an anatomic basis for their participation in improving ventricular function in damaged hearts.

	Methods

Top Abstract Introduction Methods Results Discussion Appendix: Discussion References

 
Animals
Isogenic male Lewis rats weighing 200 to 250 g (Charles River Laboratories, Laprairie, Quebec, Canada) were used as donors and recipients to simulate clinical autologous implants. Animals received humane care in compliance with the "Guide to the Care and Use of Experimental Animals" of the Canadian Council on Animal Care.

Isolation and culture of skeletal myoblast cells
After overdose with pentobarbital, the skeletal muscles of both hind quarters of adult rats were excised. As described previously, ⁶ the muscle was rinsed with 70% ethanol and then with 15 mL Hanks balanced salt solution (Life Technologies, Inc, Rockville, Md). It was then minced with scissors. After addition of 50 mL Hanks balanced salt solution, muscle fragments were sedimented at 2000 rpm for 2 minutes. The supernatant was discarded. The specimen was then incubated in 100 mL of 1% collagenase (Sigma, St Louis, Mo) and 0.2% type 1-S hyaluronidase in M199 (Life Technologies), supplemented with 5000-U/mL penicillin and 5000-µg/mL streptomycin (Life Technologies), for 60 minutes at 37°C in a shaker bath. Remaining muscle mass was then spun at 2000 rpm for 2 minutes. The sedimented muscle fragments were then incubated with 50 mL of 1% pronase solution (Sigma) for 30 minutes at 37°C to release myogenic cells. Fetal bovine serum (Life Technologies) was added to the total supernatant to halt further enzymatic cleavage processes. Isolated myoblast cells were plated on 60 mm polystyrene tissue culture dishes. (Corning Incorporated, Corning, NY) at a density of 1 x 10⁶ cells per culture dish. Growth medium, each 100 mL composed of 82 mL of M199, 7.4 mL of minimal essential medium (Sigma), 10 mL of fetal bovine serum, 5000 U/mL penicillin, 5000 µg/mL of streptomycin, 250 µL of amphotericin B, and 40 µL of gentamicin, was replaced every 24 to 48 hours. Culture dishes seeded with myogenic cells were maintained in a 37°C humidified atmosphere (95% air with 5% carbon dioxide) and passaged every 48 hours. Myoblasts were subjected to a 30-second period of treatment with trypsin (Life Technologies) diluted 10 times in M199 to facilitate detachment of cells from the tissue culture dishes.

Isolation and culture of MSCs
Isolation and primary culture of MSCs were performed according to the method of Caplan. ¹⁵ As described before, ⁹ MSCs were isolated from the femoral and tibial bones of donor rats. These cells in 10 mL of complete medium were then introduced into tissue culture dishes. Medium was completely replaced every 3 days, and the nonadherent cells were discarded. To prevent the MSCs from differentiating or slowing their rate of division, each primary culture was replated (first passaged) to three new plates when the cell density within colonies became 80% to 90% confluent, approximately 2 weeks after seeding. After the twice-passaged cells became nearly confluent, they were harvested, labeled with 4',6-diamidino-2-phenylindole (DAPI), ¹⁶ and used for the implantation experiments described here. The cells were cultured in complete medium consisting of Dulbecco modified Eagle medium containing selected lots of 10% fetal calf serum and antibiotics (100-U/mL penicillin G, 100-µg/mL streptomycin, and 0.25-µg/mL amphotericin B; Life Technologies) at 37°C in a humidified atmosphere with 5% carbon dioxide.

Skeletal myoblast and MSC labeling
Sterile DAPI solution was added to the culture medium on the day of implantation at final concentrations of 200 µg/mL for myoblasts and 50 µg/mL for MSCs. The dye was allowed to remain in the culture dishes for 30 minutes. The cells (either myoblasts or MSCs) were rinsed 6 times in Hanks balanced salt solution to remove all excess, unbound DAPI. Myoblasts and MSCs were collected (approximately 1 x 10⁶ cells for each implantation) and resuspended in minimal volume of serum-free Dulbecco modified Eagle medium. At this point they were ready for implantation into the myocardium.

Skeletal myoblast and MSC implantation
Isogenic male Lewis rats weighing 200 to 250 g served as the recipients of the donor cells. Anesthesia was induced, the animal was intubated, and a left lateral thoracotomy was performed in the fourth intercostal space. Under direct vision, 1 x 10⁶ labeled cells (skeletal myoblasts or MSCs) were injected into the left ventricular wall with a 28-gauge needle. An 8-0 Prolene suture (Ethicon Ltd, Peterborough, Ontario, Canada) was used to mark the injection track. The thoracotomy was closed, and the animal was returned to the animal care facility.

Harvesting of hearts
The rats were taken for their final experiments at the following intervals after the implantation: 1 week (n = 4 rats), 4 weeks (n = 4 rats), and 6 weeks (n = 6 rats). After overdose with pentobarbital, the hearts were exposed and injected with 100 mL saline solution (0.9%) through the posterior wall of the left ventricle, avoiding the transplanted area, then cryoembedded after protection with 20% sucrose in phosphate-buffered saline solution or embedded in paraffin after being perfusion fixed with 2% paraformaldehyde in phosphate-buffered saline solution.

Histologic and immunohistochemical examinations
The lateral wall of left ventricle was isolated from the remainder of the heart. Frozen and paraffin sections 6 µm in thickness were collected across a set of glass slides to ensure that different stains could be carried out on successive sections of tissue cut through the implantation area. One of the sections was mounted without stain for location of the DAPI-labeled donor cells under a fluorescence microscope. A successive section was stained with hematoxylin and eosin to depict nuclei, cytoplasm, and connective tissue. Other sections were selected for immunostaining of connexin-43 with rabbit polyclonal antibody (Zymed Laboratories Inc, South San Francisco, Calif). Sections were incubated in primary antibodies overnight at 4°C. Detection used secondary anti-connexin-43 antibodies conjugated with fluorescein. Combined DAPI and fluorescein images were made with simultaneous excitation filter under a reflected light fluorescence microscope (BX-FLA; Olympus America Inc, Melville, NY). Digital images, transferred to a computer equipped with Image Pro software (Media Cybernetics, LP, Silver Spring, Md), were subsequently printed.

	Results

Top Abstract Introduction Methods Results Discussion Appendix: Discussion References

 
The labeling efficiency of cultured myoblasts and MSCs with DAPI approached 100% (Figure 1, A and D, respectively). The operative mortality in our series was less than 5%.

View larger version (79K): [in this window] [in a new window]   Fig. 1. A, Cultured skeletal myoblasts stained with DAPI (blue fluorescence). Note that virtually 100% of cultured cells are labeled. 6 B, Labeled cells within host myocardium 1 week after myoblast implantation. Note undifferentiated appearance of cells. 6 C, Labeled myoblasts 4 weeks after implantation have developed into labeled myofibers. Note that these new fibers are in parallel with adjacent native, nonfluorescent cardiac myofibers. D, Cultured MSCs stained with DAPI (blue fluorescence). Note that virtually 100% of cultured cells are labeled. E, Connexin-43 expression of MSCs in specimen 6 weeks after implantation. Combined DAPI (blue fluorescence) and connexin-43 (green fluorescence) image. Anti-connexin-43 immunofluorescence is elicited by using fluorescein-conjugated secondary antibody. Positive connexin-43 staining (arrows) is found at interface between DAPI-labeled cells (arrowheads) and neighboring unlabeled cells. F, Top, DAPI-labeled cells are aligned and structurally integrated into native cardiomyofibers; native cardiomyocytes in these fibers are not labeled. Bottom, consecutive section stained with hematoxylin and eosin. Note that implanted cells are indistinguishable from native cells.

In the MSC implantation series, at 6 weeks the cells in the cardiac myofibers clearly expressed connexin-43 along the axial junctions between DAPI-labeled (implanted) cells and neighboring unlabeled cells (native cardiomyocytes; Figure 1, E). The implanted cells had changed shape, aligned in parallel to the native cardiomyocytes (Figure 1, F, top), and fully integrated into the cardiac myofibers. In fact, these cardiac myofibers containing new labeled cardiomyocytes appeared completely normal under hematoxylin and eosin staining (Figure 1, F, bottom).

	Discussion

Top Abstract Introduction Methods Results Discussion Appendix: Discussion References

 
Electromechanical coupling of myocardial cells is necessary for the myocardial syncytium to contract as a unit. Myocardial cells are connected by specialized cell-cell junctions, the intercalated discs, which allow electrical and mechanical continuity among cells. Intercalated discs consist of gap junctions (connexin-43 is the major gap junction protein ¹⁷ responsible for electrical coupling), fascia adherens junctions (N-cadherin ¹⁸ is the major protein responsible for mechanical coupling), and desmosomes. Hexamers of connexin-43 allow exchange of ions and small molecules across the membranes of adjacent cells. Recently, Reinecke and associates ¹⁹ reported electromechanical coupling between cardiomyocytes cocultured with skeletal myotubes. They demonstrated expression of cadherin and connexin-43 at junctions between cultured myotubes and cardiomyocytes. The junctions formed were responsible for electrical stimulation and contraction of myotubes. These skeletal myotube-cardiomyocyte junctions transferred calcium and dye across the membranes. These junctional proteins appeared to be downwardly regulated after intramyocardial implantation, although the reason for this was not clear. However, Robinson and colleagues ²⁰ showed in vivo that C2C12 myoblasts engrafted into murine hearts after arterial injection formed intercellular connections similar in ultrastructure to gap junctions. These junctions were rich in connexin-43, fascia adherens, and desmosomes, signifying electromechanical coupling of adjoining C2C12-native myocardial cells.

On the basis of our findings and the data reported by these other investigators, ^19,20 we propose the hypothesis that implanted cells express specific proteins to form gap junctions on contacting the host myocardium. These cell-cell junctions allow the implanted cells to communicate electrically with the rest of the myocardial syncytium and expose the implants to mechanical stretch of cardiac contraction generated by the adjacent cells. We posit that such mechanical signals cause implanted cells to alter their shape, migrate, ¹⁴ and integrate into existing myofibers (Figure 2). The orientation of new myofibers is guided by the vector of the contractions of adjacent fibers, such that they also align in parallel with other fibers in that particular layer of the myocardium. ¹⁴

View larger version (26K): [in this window] [in a new window]   Fig. 2. Schematic scenario of integration of neocardiomyocyte into native cardiac myofiber. See text for explanations.

Endothelial cells exposed to steady flow likewise realign themselves in the direction of flow, a process driven by reorganization of the cytoskeleton, as demonstrated both in vitro ²⁴ and in vivo. ²⁵ In response to mechanical strain, actin microfilaments reorganize themselves from a banding pattern around the periphery of the cell to a series of long, parallel fibers along the long axis of the aligned cell. Cytoskeletal components F-actin and vimentin-rich intermediate filaments both connect to membrane proteins (integrins) and undergo alignment with unidirectional flow. Thus the mechanical force sensed by the extracellular matrix is transmitted intracellularly by integrins to the cytoskeleton, which leads to a cellular morphologic change. Although specific data in this regard are lacking for cardiomyocytes, we suspect a similar mechanism is involved. The mechanical stress of myocardial contraction is transmitted by the cytoskeleton to the nucleus of the implanted cell, which leads to migration, changes in the cellular shape, and integration with the existing myofibers (Figure 1, F). The parallel alignment of new myofibers, as seen in Figure 1, C, can also be orchestrated by the reorganization and function of the cellular cytoskeletal system.

From this viewpoint, it is rather perplexing that myoblasts and MSCs implanted within a myocardial scar have been reported to be able to contribute to the diastolic and systolic functions of the hearts. In these studies the cells were injected into the center of a scar caused by cryoinjury or coronary artery ligation. Although these cells seemed to undergo myogenic differentiation, they did not appear to connect and integrate with native cardiac fibers and were without evidence of gap junction formation. How such cells can contribute to systolic function and improve systolic work index ⁷ is not clear. Some data obtained with an isovolumic Langendorff preparation may be questioned, because the investigators used resting ventricular balloon volumes to represent preloads in constructing a Frank-Starling curve, despite the fact the cardiac sizes were significantly different between their comparison groups. ¹⁰ The hearts that received cell implants seem to be smaller than control hearts, perhaps because of reduced scar expansion and ventricular remodeling. Curiously, even implantation of smooth muscle cells has been reported to reduce cardiac dilatation. ²⁶ Such observations have led to the suggestion that presence of such cells within the scar changes the physical property of the scar tissue, exerting a shielding effect to reduce scar expansion. ¹¹ This explanation, however, may not be consistent with a report that cell implantation in fact improved diastolic compliance of the scar tissue, as measured with ultrasonic microcrystals placed across the scar tissue. ⁷ Thus there remains uncertainty regarding the reliability and mechanisms of putative improvement in cardiac function after cell implantation inside myocardial scars.

Study limitations
In this kind of study, the technique of cell labeling used is of paramount importance, because it is crucial for differentiating myocytes derived from the implanted cells from those of the native myocardium. Although DAPI, used in this study for cell labeling, had been used and reported on by earlier investigators, ^27,28 there were some concerns regarding its specificity, because the labeled cells might release DAPI molecules on their death after implantation, and leaked DAPI could then label the native myocytes in vivo to give false-positive results. Our own validation study to exclude this possibility has previously been published. ⁶ We tested the worst case scenario by directly injecting DAPI into the myocardium, and we confirmed that even with massive doses relative to that which might leak out from dead cells, DAPI failed to stain any native cells in vivo. We postulate that this is due to the rapid washout of free DAPI molecules in vivo, because the established labeling protocol in vitro requires incubation of these cells with DAPI for 30 to 60 minutes. Thus the limitation of using DAPI is not its possible false-positive results, but rather the risk of false-negative results if the implanted cells had divided and multiplied many times before terminal differentiation. If this were the case, the progeny cells might not be labeled, giving false-negative results that could affect the quantitative results. We did not attempt quantitative analysis of our data, which was a limitation of this study.

The major advantages of DAPI relative to other techniques are that its labeling efficiency is virtually 100% and it is not toxic to the cells. It is also known that DAPI has greatest affinity to bind the regions of DNA rich in adenine-thymine pairs, but in high concentrations it can also bind to tubulin and microtubules in the cytoplasm. ²⁹ Because in our myoblast implant experiments we used 200 µg/mL of DAPI, both the nuclei and cytoplasm were stained (Figure 1, B and C). For the MSC experiments, however, the DAPI used was 50 µg/mL, and thus only the nuclei were fluorescent (Figure 1, E and F). The discrepancy in the DAPI concentrations used is a reflection of our refinement in the labeling technique as we studied MSCs after our earlier experience with the myoblasts. This limitation does not affect the validity of our findings. Further investigations, such as correlating our observations with ultrastructures and functional data, are desirable in future studies.

	Appendix: Discussion

Top Abstract Introduction Methods Results Discussion Appendix: Discussion References

 
Dr Alain Carpentier (Paris, France). I enjoyed this presentation, particularly the investigation of whether muscular cells are more appropriate for this type of cellular cardiomyoplasty. The ultimate goal of cellular cardiomyoplasty is to enhance contractility of the myocardium. To do so, you must demonstrate not only the survival of the implanted cells but also the transformation of the metabolism of these cells from glycolytic metabolism to oxidative metabolism. Were you able to determine that by using a specific antibody, and what did you find?

Dr Chedrawy. We have not actually looked at the metabolic aspects of cellular cardiomyoplasty. The study focused solely on the structural aspects, in hopes of providing an anatomic basis for the functional improvements that have been described. I agree that this is something to be looked into in further investigations.

Sir Magdi Yacoub (London, United Kingdom). I enjoyed your presentation. I have several questions. First, did you select your stem cells by flow cytometry or selecting lin negative, for example? Second, when you looked at the cells, did you look for cardiomyocyte-specific transcription factors, such as MIF-2 or GATA-4? For these myocytes or myogenic cells to function, especially if they are derived from bone marrow, they should have cardiac-specific sarcomeric proteins. Did you find, for example, troponin I or other myocardial-specific sarcomeric isoforms, because that would be essential? Finally, what do you think is the origin of your connexin-43? Is it from the native cardiomyocytes or from the transplanted cells?

Dr Chedrawy. With respect to the first question, the MSCs were isolated according to the method of Caplan, in which the marrow was harvested from the long bones of the rats, the cells were plated on a culture dish, and the supernatant was discarded. All the cells that adhered to the culture dish, which is the distinguishing property of these cells, were used for the MSC implantation.

With respect to your second question, we did not actually look at MIF-2 as a transcription factor. We looked strictly at the implantation process and the anatomic structural integration.

With respect to your third question, we did look at cardiac-specific contractile proteins. In our case, sarcomeric myosin heavy chain protein was expressed by these implanted MSCs. We did not look at troponin I in particular.

With respect to your fourth question regarding connexin-43 expression, I am not really sure whether the MSCs themselves would express connexin-43. However, we know from in vitro studies by Dr Charles Murray's group that coculture of skeletal myotubes with cardiac cells leads to coexpression of connexin-43. So perhaps some similar mechanism is operating in this case, although I do not know for sure.

Dr Robert C. Robbins (Stanford, Calif). I believe that the title of your article is a bit misleading. These really are not stem cells, or at least you have not proved that they are stem cells. I probably missed it, but did you create any ischemia or any injury to the myocardium?

Dr Chedrawy. With respect to your first point, about calling the MSCs stem cells, the pluripotent nature of these MSCs is being elucidated on a monthly basis, and more and more tissues of mesenchymal, ectodermal, and neurodermal origin are being harvested from these stem cells. That is why we refer to them as stem cells and not as mesenchymal tissue origin cells.

With respect to your second concern, we actually injected all these cells into normal myocardium. We wanted to expose these cells to the normal cardiac milieu in the event that they would undergo a milieu-dependent differentiation and transform into cardiomyocytes.

Dr Robbins. I have two quick follow-up questions. First, do you have any scanning electron microscopy to further delineate the ultrastructure? Second, what do you think about your cells in an ischemic model, such as cryoinjury or ligation of a coronary artery?

Dr Chedrawy. With respect to your first question, scanning electron microscopy was not included as part of the study. However, I agree that it would definitely be of value to clarify the ultrastructure of these cells, especially the cell-to-cell junctions.

With respect to your second question, we have implanted these cells in ischemic models, both cryoinjury and coronary ligation. However, our biggest concern was the actual survival of these cells within the myocardially induced scar.

Dr Robbins. And did they survive?

Dr Chedrawy. As long as 2 weeks.

Dr Richard D. Weisel (Toronto, Ontario, Canada). What do you think happens in the ischemic model?

Dr Chedrawy. I think that the biggest concern with the ischemic model is that they are not receiving that stimulus to actually convert into myocardial cells because they are not exposed to the normal environmental cues in the myocardium.

Dr Weisel. To what do they convert?

Dr Chedrawy. Various forms of fibroblasts.

Dr Weisel. So maybe that is not the right answer for infarct replacement.

Dr Joseph B. Shrager (Philadelphia, Pa). In terms of showing differentiation toward cardiac muscle, if you are going to use expression of a myosin heavy chain to try to establish this, you have to use something other than generic sarcomeric myosin heavy chain. The cardiac myosin heavy chain is the only one that is found only in cardiac muscle. Any of the other isoforms of myosin heavy chain are found in skeletal muscle, and therefore their presence does not establish cardiac differentiation.

Dr Chedrawy. We did not look at an myosin heavy chain. We strictly looked at sarcomeric myosin heavy chain. However, you are right, we could have stained for other cardiac-specific proteins.

	Footnotes

 
Read at the Eighty-first Annual Meeting of The American Association for Thoracic Surgery, San Diego, Calif, May 6-9, 2001 (C. Walton Lillehei Resident Forum Session).

	References

Top Abstract Introduction Methods Results Discussion Appendix: Discussion References

 

1. Soonpaa MH, Koh GY, Klug MG, Field LJ. Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium. Science. 1994;264:98-101.[Abstract/Free Full Text]
   
2. Chiu, RC, Zibaitis A, Kao RL. Cellular cardiomyoplasty: Myocardial regeneration with satellite cell implantation. Ann Thorac Surg. 1995;60:12-8.[Abstract/Free Full Text]
   
3. Yoon PD, Kao RL, Magovern GJ. Myocardial regeneration: transplanting satellite cells into damaged myocardium Tex Heart Inst J. 1995;22:119-25.
   
4. Atkins BZ, Lewis CW, Kraus WE, Hutcheson KA, Glower DD, Taylor DA. Intracardiac transplantation of skeletal myoblasts yields two populations of striated cells in situ. Ann Thorac Surg. 1999;67:124-9.[Abstract/Free Full Text]
   
5. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD. Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest. 1996;98:2512-23.[Medline]
   
6. Dorfman J, Duong M, Zibaitis A, Pelletier M, Shum-Tim D, Li C, et al. Myocardial tissue engineering with autologous myoblast implantation. J Thorac Cardiovasc Surg. 1998;116:744-51.[Abstract/Free Full Text]
   
7. Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC, Hutcheson KA, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med. 1998;4:929-33.[Medline]
   
8. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest. 1999;103:697-705.[Medline]
   
9. Wang JS, Shum-Tim D, Galipeau J, Chedrawy E, Eliopoulos N, Chiu RC. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg. 2000;120:999-1006.[Abstract/Free Full Text]
   
10. Tomita S, Li RK, Weisel RD, Mickle DA, Kim EJ, Sakai T, et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation. 1999;100 Suppl:II247-56.
    
11. Chiu RC. Cardiac cell transplantation: The autologous skeletal myoblast implantation for myocardial regeneration. Adv Card Surg. 1999;11:69-98.[Medline]
    
12. Bianco P, Gehron Robey P. Marrow stromal stem cells. J Clin Invest. 2000;105:1663-8.[Medline]
    
13. Rohen JW, Yokochi C. Color atlas of anatomy. 2nd ed. p. New York: Igaku-Shoin; 1988. p. 231.
    
14. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Molecular biology of the cell. 2nd ed. New York: Garland Publishing; 1989. p. 613-80.
    
15. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:641-50.[Medline]
    
16. Kapuscinski J. DAPI: a DNA-specific fluorescent probe. Biotech Histochem. 1995;70:220-33.[Medline]
    
17. Beyer EC, Paul DL, Goodenough DA. Connexin 43: a protein from rat heart homologous to a gap junction protein from liver. J Cell Biol. 1987;105:2621-9.[Abstract/Free Full Text]
    
18. Volk T, Geiger B. A 135-kd membrane protein of intercellular adherens junctions. EMBO J 1984;3:2249-60.[Medline]
    
19. Reinecke H, MacDonald GH, Hauschka SD, Murry CE. Electromechanical coupling between skeletal and cardiac muscle: implications for infarct repair. J Cell Biol. 2000;149:731-40.[Abstract/Free Full Text]
    
20. Robinson SW, Cho PW, Levitsky HI, Olson JL, Hruban RH, Acker MA, et al. Arterial delivery of genetically labeled skeletal myoblasts to the murine heart: long-term survival and phenotypic modification of implanted myoblasts. Cell Transplant. 1996;5:77-91.[Medline]
    
21. Kanda K, Matsuda T. Mechanical stress-induced orientation and ultrastructural change of smooth muscle cells cultured in three-dimensional collagen lattices. Cell Transplant. 1994;3:481-92.[Medline]
    
22. Wilson E, Sudhir K, Ives HE. Mechanical strain of rat vascular smooth muscle cells is sensed by specific extracellular matrix/integrin interactions. J Clin Invest. 1995;96:2364-72.
    
23. Niklason LE, Gao J, Abbott WM, Hirschi KK, Houser S, Marini R, et al. Functional arteries grown in vitro. Science. 1999;284:489-93.[Abstract/Free Full Text]
    
24. Dewey CF, Bussolafi SR, Gimbrone MA, Davies PF. The dynamic response of vascular endothelial cells to fluid shear stress. J Biomech Eng. 1981;103:177-88.[Medline]
    
25. Langille BL, Graham JJ, Kim D, Gotlieb AI. Dynamics of shear-induced redistribution of F-actin in endothelial cells in vivo. Arteriosclerosis Thromb. 1991;11:1814-20.[Abstract/Free Full Text]
    
26. Yoo KJ, Li RK, Weisel RD, Mickle DA, Li G, Yau TM. Autologous smooth muscle cell transplantation improved heart function in dilated cardiomyopathy. Ann Thorac Surg. 2000;70:859-65.[Abstract/Free Full Text]
    
27. Tamowski BI, Spinale FG, Nicholson JH. DAPI as a useful stain for nuclear quantitation. Biotech Histochem. 1991;66:296-302.
    
28. Kapuscinski J. A DNA-specific fluorescent probe. Biotech Histochem. 1995;70:220-33.
    
29. Bonne D, Heusele C, Simon C, Pantaloni D: 4',6-diamidino-2-phenylindole, a fluorescent probe for tubulin and microtubules. J Biol Chem. 1985;260:2819-25.[Abstract/Free Full Text]
    

This article has been cited by other articles:

				M. Tumkosit, C. G. Martin, E. Bayram, T. M. Morgan, K. S. Lane, P. Rerkpattanapipat, C. A. Hamilton, K. M. Link, and W. G. Hundley Left Ventricular Spherical Remodeling and Apical Myocardial Relaxation: Cardiovascular MR Imaging Measurement of Myocardial Segments Radiology, August 1, 2007; 244(2): 411 - 418. [Abstract] [Full Text] [PDF]

				G. Steinhoff, Y.-H. Choi, and C. Stamm Intramyocardial bone marrow stem cell treatment for myocardial regeneration Eur. Heart J. Suppl., December 1, 2006; 8(suppl_H): H32 - H39. [Abstract] [Full Text] [PDF]

				J. Tang, Q. Xie, G. Pan, J. Wang, and M. Wang Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 353 - 361. [Abstract] [Full Text] [PDF]

				S. C. Dudley Jr Beware of Cells Bearing Gifts: Cell Replacement Therapy and Arrhythmic Risk Circ. Res., July 22, 2005; 97(2): 99 - 101. [Full Text] [PDF]

				M. Xu, M. Wani, Y.-S. Dai, J. Wang, M. Yan, A. Ayub, and M. Ashraf Differentiation of Bone Marrow Stromal Cells Into the Cardiac Phenotype Requires Intercellular Communication With Myocytes Circulation, October 26, 2004; 110(17): 2658 - 2665. [Abstract] [Full Text] [PDF]

				J. C. Chachques, C. Acar, J. Herreros, J. C. Trainini, F. Prosper, N. D'Attellis, J.-N. Fabiani, and A. F. Carpentier Cellular cardiomyoplasty: clinical application Ann. Thorac. Surg., March 1, 2004; 77(3): 1121 - 1130. [Abstract] [Full Text] [PDF]

				Y.-F. Xiao, J.-Y. Min, and J. P. Morgan Immunosuppression and xenotransplantation of cells for cardiac repair Ann. Thorac. Surg., February 1, 2004; 77(2): 737 - 744. [Abstract] [Full Text] [PDF]

				S. Taheri Myogenesis after myocardial stem cell transplantation J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 2116 - 2117. [Full Text] [PDF]

				J. D. Dowell, M. Rubart, K. B.S. Pasumarthi, M. H. Soonpaa, and L. J. Field Myocyte and myogenic stem cell transplantation in the heart Cardiovasc Res, May 1, 2003; 58(2): 336 - 350. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Edgar G. Chedrawy Dao M. Nguyen Dominique Shum-Tim Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chedrawy, E. G. Articles by Chiu, R. C. J. Search for Related Content PubMed PubMed Citation Articles by Chedrawy, E. G. Articles by Chiu, R. C. J. Related Collections Molecular biology